Bluesky Facebook Reddit Email

Evaluation of in-vitro activity of ceftazidime-avibactam against carbapenem-resistant gram-negative bacteria: A cross-sectional study from Pakistan

05.14.25 | Xia & He Publishing Inc.

Garmin GPSMAP 67i with inReach

Garmin GPSMAP 67i with inReach provides rugged GNSS navigation, satellite messaging, and SOS for backcountry geology and climate field teams.

Escalating antimicrobial resistance is a global threat, emphasizing the need to explore alternative treatment options. Hence, we aimed to explore the in-vitro activity of ceftazidime-avibactam (CAZ-AVI) in clinical isolates of carbapenem-resistant gram-negative bacteria.

This was an observational, cross-sectional study conducted at the Microbiology Department of Indus Hospital, Karachi, Pakistan, from January 2023 to October 2024. Carbapenem-resistant gram-negative rods isolated from clinical specimens received from the outpatient, emergency, and inpatient departments were included. Consecutive, non-probability sampling was employed for the collection of isolates. Identification of the organisms was confirmed using API® ID strips, and antimicrobial susceptibility for carbapenems and CAZ-AVI was determined via the Kirby-Bauer disc diffusion method.

A total of 158 bacterial isolates were characterized as carbapenem-resistant. Of these, 92 (58%) were Enterobacterales , and 66 (42%) were Pseudomonas aeruginosa . CAZ-AVI was susceptible in 17 (11%) of the isolates, of which four (24%) were Klebsiella spp . and Escherichia coli each, and nine (52%) were P. aeruginosa . CAZ-AVI-susceptible strains were predominant among patients aged 26–50 years (n = 6; 35%), most of whom were females (n = 10; 59%) and inpatients (n = 8; 47%). Clinical samples from patients with urinary tract infections grew the most CAZ-AVI-susceptible strains (n = 9; 53%).

Our study demonstrated low CAZ-AVI susceptibility in our carbapenem-resistant gram-negative bacterial strains. Understanding regional antimicrobial patterns in multidrug-resistant bacteria is crucial for the effective use of CAZ-AVI, along with the strict implementation of strategies for controlling antimicrobial resistance.

https://www.xiahepublishing.com/2572-5505/JERP-2025-00001

The study was recently published in the Journal of Exploratory Research in Pharmacology .

Journal of Exploratory Research in Pharmacology (JERP) publishes original innovative exploratory research articles, state-of-the-art reviews, editorials, short communications that focus on novel findings and the most recent advances in basic and clinical pharmacology, covering topics from drug research, drug development, clinical trials and application.

Follow us on X: @xiahepublishing

Follow us on LinkedIn: Xia & He Publishing Inc.

Journal of Exploratory Research in Pharmacology

10.14218/JERP.2025.00001

Evaluation of In-vitro Activity of Ceftazidime-avibactam Against Carbapenem-resistant Gram-negative Bacteria: A Cross-sectional Study from Pakistan

25-Mar-2025

Keywords

Article Information

Contact Information

Shelly Zhang
Xia & He Publishing Inc.
service@xiahepublishing.com

Source

How to Cite This Article

APA:
Xia & He Publishing Inc.. (2025, May 14). Evaluation of in-vitro activity of ceftazidime-avibactam against carbapenem-resistant gram-negative bacteria: A cross-sectional study from Pakistan. Brightsurf News. https://www.brightsurf.com/news/LRDGN958/evaluation-of-in-vitro-activity-of-ceftazidime-avibactam-against-carbapenem-resistant-gram-negative-bacteria-a-cross-sectional-study-from-pakistan.html
MLA:
"Evaluation of in-vitro activity of ceftazidime-avibactam against carbapenem-resistant gram-negative bacteria: A cross-sectional study from Pakistan." Brightsurf News, May. 14 2025, https://www.brightsurf.com/news/LRDGN958/evaluation-of-in-vitro-activity-of-ceftazidime-avibactam-against-carbapenem-resistant-gram-negative-bacteria-a-cross-sectional-study-from-pakistan.html.